Stock Analysis on Net

AbbVie Inc. (NYSE:ABBV)

$24.99

Common-Size Income Statement
Quarterly Data

AbbVie Inc., common-size consolidated income statement (quarterly data)

Microsoft Excel
3 months ended: Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Net revenues
Cost of products sold
Gross margin
Selling, general and administrative
Research and development
Acquired IPR&D and milestones
Other operating income (expense), net
Operating earnings
Interest expense, net
Net foreign exchange gain (loss)
Other income (expense), net
Earnings (loss) before income tax (expense) benefit
Income tax (expense) benefit
Net earnings (loss)
Net (earnings) loss attributable to noncontrolling interest
Net earnings (loss) attributable to AbbVie Inc.

Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Income statement item Description The company
Operating earnings The net result for the period of deducting operating expenses from operating revenues. AbbVie Inc. operating earnings as a percentage of net revenues increased from Q1 2024 to Q2 2024 but then slightly decreased from Q2 2024 to Q3 2024.
Earnings (loss) before income tax (expense) benefit Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. AbbVie Inc. earnings (loss) before income tax (expense) benefit as a percentage of net revenues increased from Q1 2024 to Q2 2024 but then slightly decreased from Q2 2024 to Q3 2024 not reaching Q1 2024 level.
Net earnings (loss) attributable to AbbVie Inc. The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. AbbVie Inc. net earnings (loss) attributable to AbbVie Inc. as a percentage of net revenues decreased from Q1 2024 to Q2 2024 but then increased from Q2 2024 to Q3 2024 not reaching Q1 2024 level.